OBJECTIVES: A standardized definition for primary graft dysfunction (PGD) after cardiac transplantation was recently proposed by the International Society of Heart and Lung Transplantation (ISHLT). We sought to characterize the outcomes associated with and identify risk factors for PGD following cardiac transplantation using these criteria at a high volume centre.
INTRODUCTION
Primary graft dysfunction (PGD) is the most common cause of death within 30 days of cardiac transplantation [1] . The most recent report from the International Society for Heart and Lung Transplantation (ISHLT) Registry reported that 42.6% of deaths within 30 days after transplant were due to PGD [2] . Due to the lack of standardized criteria for its diagnosis, the incidence of PGD reported in the literature has varied widely between 2 and 24% [3] [4] [5] [6] [7] Proposed definitions have included various diagnostic criteria including timing of onset, echocardiographic evidence, haemodynamic measures and/or requirements for inotropic or mechanical support. The inconsistency in applied definitions prevents generalization of results from one centre and/or era to others. The lack of standardization has also resulted in the identification of dozens of donor, recipient and procedural factors that may increase the risk for PGD [8] .
To address this issue, the ISHLT recently published a consensus document with standardized criteria for PGD diagnosis following cardiac transplantation [9] . The ISHLT consensus committee also emphasized that the diagnosis of PGD must be made within 24 h after completion of the transplantation surgery and that other discernible causes such as hyper-acute rejection, pulmonary hypertension, or known surgical complications must be ruled out in order to diagnose PGD. The new ISHLT criteria for PGD must be validated in a sample cohort, but the major transplantation databases [United Network for Organ Sharing (UNOS) and Eurotransplant] have not incorporated these criteria to document PGD. Therefore, the aim of this study is to validate the ISHLT criteria through their application to a series of adult cardiac transplantations from a high volume centre by: (1) determining the impact of PGD on outcomes up to 1-year following transplantation and (2) identifying risk factors for the development of PGD.
METHODS

Patients and definitions
This study was approved by the Institutional Review Board at Baylor University Medical Center, and informed consent was waived given the retrospective nature of the study. The medical records of 201 patients undergoing heart transplantation procedures from November 2012 to March 2015 were reviewed. Those who underwent multi-organ transplants were excluded (six kidney/heart, three liver/heart and one heart/lung). Information about the respective donors was also reviewed. Recipient characteristics examined were demographics, etiology of heart failure, comorbidities, mechanical assistance prior to transplant, UNOS status, cytomegalovirus (CMV) status, prior sternotomy, wait list time and subjective global assessment (SGA) score. Donor characteristics included demographics, cause of death, donor heart measurements and haemodynamics, CMV status and rates of prior cardiopulmonary resuscitation (CPR). Procedural characteristics included donor/recipient size mismatch [by weight ratio, body weight percent difference and predicted heart mass (pHM) percent differences], distance of donor centre from recipient centre and cold ischemia time. pHM was calculated using previously published equations that incorporate height, weight, age and sex to account for variations in heart mass due to gender and age at a constant body mass [10] [11] [12] . Donor/recipient percent difference measurements were calculated as follows:
The ISHLT recently published standardized criteria to diagnose PGD following cardiac transplantation (Table 1) [9, 13] . The ISHLT consensus committee introduced two new features to the diagnosis of PGD that had not been previously reported in the literature: (i) a distinction between PGD due to left ventricular or biventricular failure (PGD-LV) and PGD due to right ventricular failure (PGD-RV) and (ii) a 3-level grading system for PGD-LV. Despite the ISHLT consensus committee's recommendation for a distinction between PGD-RV and PGD-LV, it was not feasible to incorporate this distinction in our study. Specifically, our centre's clinical approach to patients with evidence of PGD precluded such analysis. The haemodynamic criteria used to distinguish PGD-RV from PGD-LV rely on measurements not routinely collected at our centre, particularly pulmonary capillary wedge pressure (PCWP), due to safety concerns regarding the serial acquisition of such metrics by non-physicians. Additionally, no right ventricular assist devices (RVADs) were placed in our patient cohort because extracorporeal membrane oxygenation (ECMO) therapy has become our preferred therapeutic modality for all patients who require support beyond maximum inotropic therapy. Patients were therefore assigned only to none, mild, moderate, or severe PGD-LV based upon the ISHLT criteria within the first 24 h after the completion of the transplantation procedure. In order to facilitate statistical analysis, patients were separated into two groups: none/mild PGD and moderate/severe PGD. Infectious complications following transplantation were catalogued as previously defined [14] .
Transplant criteria and immunosuppression
The same transplantation protocol was implemented throughout the study period. A cardioplegia needle was inserted into the Inotrope score = dopamine (Â1) + dobutamine (Â1) + amrinone (Â1) + milrinone (Â15) + epinephrine (Â100) + norepinephrine (Â100) with each drug dosed in mg/kg/min.
ascending aorta at the initiation of organ procurement. The ascending aorta was cross-clamped, and 2 L of Belzar UW solution was used to arrest the heart. The organ was closely inspected for any pathology after cardiectomy. Then, the donor heart was placed in a sterile container, and transported in a portable cooler on ice. After the organ arrived to our centre, it was removed from the container and placed into the operating field. A 500 mL volume of cardioplegia was administered down the aortic root immediately prior to implantation. Intermittent doses of cardioplegia were given between each anastomosis, and orthotopic heart transplantation was performed using the bicaval technique. The same immunosuppression protocol was prescribed to all patients throughout the study period. At the time of transplantation, recipients were given mycophenolate mofetil 2 g intravenously [IV; or 1 g IV if white blood cell count (WBC) less than 4 Â 10 3 /mL or recipient age over 60] and solumedrol 1 g IV in the operating room. They also received a single dose of basiliximab 20 mg IV in the operating room and again on postoperative day 4. During the first 24 h after surgery, patients received mycophenolate mofetil 1 g IV every 12 h (or 500 mg every 12 h if WBC less than 4 Â 10 3 /mL or recipient age over 60) and methylprednisolone 125 mg IV every 8 h. Thereafter, patients receive a steroid taper [methylprednisolone IV, transitioned to prednisone taper orally (PO) starting at 1 mg/kg], an antiproliferative agent (mycophenolate mofetil 1000 mg PO every 12 h), and a calcineurin antagonist (tacrolimus PO with doses targeted to goal levels of 12-15 ng/mL in the first 3 months post-transplant, 10-12 ng/mL in months 3-6, 8-10 ng/mL in months 6-12, and 4-8 ng/mL after 1 year).
Statistical analysis
Recipient-related, donor-related and procedure-related characteristics were summarized and compared for their association with moderate/severe PGD. These univariate associations were tested for statistical significance by using v 2 test for categorical data or Wilcoxon rank-sum test for continuous variables. All statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA).
Univariate logistic regression results were used as a conservative screening tool to identify a subset of potential predictors for moderate/severe PGD. Donor, recipient and procedure characteristics related to moderate/severe PGD at values of P < 0.25 were tested for inclusion in the final multivariate analysis. Multivariate logistic regression was used to adjust for potential confounding. A stepwise Akaike information criterion (AIC) bestsubsets approach was used to identify the final multivariable model. The approach facilitates selection among AIC optimal models based on clinical and statistical considerations [15] . Final results are expressed as multivariate odds ratios (OR) and 95% confidence intervals (CI). The Kaplan-Meier method was used to estimate cumulative survival up to 1-year after cardiac transplantation procedure. Patient survival curves were compared using the log-rank test.
RESULTS
During the 30-month study period, we performed 191 consecutive, isolated heart transplantation procedures. The mean recipient age at the time of transplantation was 57 ± 11 years (range 42-65 years) and 25% of patients were female. The etiology of heart failure was evenly divided between ischemic cardiomyopathy (50%) and non-ischemic cardiomyopathy (50%). The recipient UNOS statuses were recorded as: 1A (38%), 1B (53%) and 2 (9%). Mean allograft hypothermic ischemic time was 228 ± 61 min.
A total of 59 (30%) patients were diagnosed with PGD using the ISHLT criteria: 35 (18%) mild, 8 (4%) moderate and 16 (8%) severe. Patients were grouped into none/mild PGD and moderate/severe PGD groups for statistical comparisons. Recipientrelated, donor-related and procedure-related variables for each group are summarized in Table 2 .
Postoperative outcomes and complications for each group are summarized in Table 3 [16] . There were six (3%) in-hospital/30-day mortalities in the cohort, all of which occurred in patients with severe PGD. Thus, short-term mortality was much higher in the moderate/severe PGD group (25%) as compared to the none/mild PGD group (0%). Patients diagnosed with moderate/ severe PGD developed more postoperative infections (pneumonia, sepsis and mediastinitis), required more transfusions and reoperations for bleeding, experienced a higher rate of acute renal failure requiring dialysis and had increased inotrope scores (Table 3) . Patients who developed moderate/severe PGD also had longer intensive care unit (ICU) length of stay (LOS; 22 ± 21 days vs 4 ± 6 days, P < 0.001) and total postoperative LOS (27 ± 20 days vs 11 ± 9 days, P <0.001) as compared to patients with none/ mild PGD.
Survival to 1-year post-transplantation was diminished with increasing severity of PGD ( Fig. 1 ; none 93%, mild 94%, moderate 75% and severe 44%; log-rank P < 0.001). The survival curves diverged during the first 3 months following transplantation, but were similar after this initial postoperative period. To analyse the duration of the effect of PGD on survival, we also estimated conditioned mortality monthly following transplantation. Patients who survived 1 and 2 months following transplantation still demonstrated increased mortality with increasing severity of PGD (log-rank P = 0.002). However, the conditioned survival estimates at 3-months post-transplantation was not significantly different between PGD severities (log-rank P = 0.37).
The following preoperative variables were associated with moderate/severe PGD by univariate logistic regression analysis (P < 0.05): increased recipient body mass index, elevated preoperative creatinine, recipient hospitalized at the time of transplantation, ischemic cardiomyopathy, and undersized donor (by difference in pHM > _ 30%) and requirement for ECMO prior to transplantation (Table 4) . Although a requirement for ECMO support prior to transplantation was a significant univariate predictor of moderate/severe PGD, this factor was precluded from subsequent multivariate analysis given the limited number of patients in the study cohort requiring pretransplant ECMO (5/191; 2.6%). Upon multivariate logistic regression analysis, elevated preoperative creatinine, undersized donor (by difference in pHM > _ 30%), and recipient hospitalized at the time of transplantation were independently associated with moderate/severe PGD. A graphical representation of the multivariate adjusted probability of moderate/severe PGD according to these variables is presented in Fig. 2 . The model is highly discriminative (c-statistic = 0.765).
DISCUSSION
PGD is the most common cause of death following cardiac transplantation [1] . Due to a lack of standardized criteria for PGD diagnosis, previous studies have reported widely variable rates of PGD and dozens of potential risk factors for this complication [2] [3] [4] [5] [6] [7] [8] . Recently, the ISHLT proposed a standard set of criteria for the diagnosis of PGD to address this issue [9] . To the authors' knowledge, our report is the first to apply the new ISHLT criteria to a series of patients in order to examine outcomes of and identify risk factors for PGD at a high volume transplant centre. In our series of 191 consecutive, isolated cardiac transplantations performed within a 30-month period, the total incidence of PGD was 30%. Severity of PGD in this cohort was stratified to (3) 1 (1) (2) 2 (6) 5 (3) 1 (13) 1 (6) 2 (8) 0.21 Sternal wound infection (without mediastinitis)
Sternal wound infection (with mediastinitis) (13) 2 (13) 3 (13) 0.002* Bacteremia 3 (2) 2 (6) 5 (3) 2 (25) 1 (6) 3 (13) mild (18%), moderate (4%) and severe (8%). Other reports have described incidences of non-stratified PGD ranging from 2 to 24% [2] [3] [4] [5] [6] [7] . Although the total incidence of PGD in our cohort is the highest reported in any study of adult patients, this likely reflects the liberal criteria for PGD proposed by the ISHLT. The ISHLT recognized that this definition would result in a significant number of patients being diagnosed with PGD, and therefore the committee stratified the diagnosis of PGD into mild, moderate and severe classifications [9] . The variety of non-stratified diagnostic criteria applied in published studies likely explains the significant variability in previously reported PGD incidence. Some studies have applied narrow definitions that restrict the diagnosis of PGD to the most severe cases, such as those resulting in mortality or early requirement for VAD, in an effort to implement objective, easy-to-apply criteria. These studies generally report a lower incidence of PGD (2-3%) [3, 4] . On the other hand, studies that incorporate more liberal definitions (for example, those that incorporate additional criteria such as early inotropic support) have in contrast reported a higher incidence of PGD (9-24%) [5] [6] [7] .
The majority of patients with PGD in our cohort met the criteria only for mild PGD (35/59; 59%). The remaining 24 patients with moderate or severe PGD comprise only 13% of the total cohort, an incidence that falls in the middle of the range previously reported. Of note, there was no difference in the 30-day/in-hospital or 1-year mortality of patients with mild PGD versus those without PGD. Taken together, these findings suggest that the ISHLT category for mild PGD may not have significant clinical relevance in terms of mortality. A diagnosis of mild PGD may portend an increased risk for morbidity, though the rates of postoperative complications were similar between the none and the mild PGD cohorts in our study. However, such a comparison was not the primary aim of our analysis, and a larger sample size is probably necessary to determine whether mild PGD truly reflects any increase in morbidity.
The survival of patients with mild PGD was similar to that of patients without PGD, but diagnosis of moderate or severe PGD was indeed associated with increased mortality. In-hospital/30-day mortality for patients with moderate/severe PGD was 25%, whereas none of the patients with none/mild PGD suffered early mortality. Patients diagnosed with moderate/severe PGD also experienced higher transfusion burdens and increased rates of reoperation for bleeding and post-operative renal failure requiring dialysis. Not surprisingly, ICU and total postoperative LOS were longer in the moderate/severe PGD group as compared to the none/mild PGD group, reflecting the aggressive therapy and increased resource utilization required to treat patients with clinically significant (moderate/severe) PGD. This group also experienced increased rates of infections, most likely due to the increased LOS required following transplantation.
Although PGD was previously thought to impact survival primarily within a 30-day postoperative period, recent evidence suggests that PGD may affect survival for several months beyond the initial post-transplantation window [17] . Our study identified that moderate/severe PGD negatively impacted survival up to 3 months following transplantation, lending further credence to this new understanding of the mid-term prognosis associated with PGD. Downstream consequences of PGD, including sepsis and multiorgan failure, likely increase mortality for several months following transplantation, even if patients with these unfortunate sequelae live beyond 30-days [17] . Cumulative survival analysis after 3 months, however, was similar between the two groups, suggesting that total recovery of the graft occurs by approximately 90 days and is maintained at 1-year follow-up. This finding should be reassuring for patients initially diagnosed with PGD who survive this critical period.
The pathogenesis of PGD has not been clearly delineated, though its origin is believed to be multifactorial. After multivariate regression, elevated preoperative creatinine, recipient hospitalized at time of transplant and undersized donor (by difference in pHM > _ 30%) were found to be independently predictive of PGD in our analysis. Numerous clinical markers indicating a more severe pretransplant condition of the recipient, including requirement for inotropic or mechanical support, have been repeatedly identified as risk factors for PGD [3, 18, 19] , suggesting that placing a donor heart in a 'hostile' recipient environment increases the risk for this complication. Our study identified recipient hospitalization at the time of transplantation, a potential marker for some or all of the variables that may suggest a hostile recipient environment, as a risk factor for PGD.
The negative impact of compromised renal function on outcomes following essentially any cardiothoracic procedure is firmly established [20] , and, thus, preoperative creatinine levels weigh heavily in the Society of Thoracic Surgeons cardiac surgery risk models [21, 22] . That the likelihood for development of PGD increased with diminishing renal function in our cohort is consistent with this principle. The renal function of heart transplant recipients may face additional stressors beyond that of openchest surgery itself. Transplant recipients are dosed with nephrotoxic immunosuppressant agents including calcineurin inhibitors. The inflammatory response induced by the transplantation of a foreign object into the recipient's body may further compromise renal function postoperatively. Therefore, the preoperative creatinine of heart transplant recipients in particular may be of even greater import as compared to other cardiothoracic procedures, especially given the increased risk for moderate/severe PGD faced by patients with elevated preoperative levels.
Undersized donor by body weight alone has previously been associated with PGD [3, 18] . However, variations in age and sex have been proven to affect the heart mass of donors with the same body weight. Formulas to estimate heart mass (pHM) that incorporate donor age, sex, weight and height to account for these additional factors have therefore been developed to provide clinicians with better information regarding donor-recipient size mismatches [11, 12] . Undersized donor hearts as defined by a difference in pHM have already been shown to negatively influence survival following heart transplantation [10] . Our study is the first to demonstrate an association between undersized donor hearts by pHM and the development of PGD postoperatively. Although the transplantation of marginal donor hearts (including undersized donor hearts) can be performed safely [5] , our analysis suggests that there is a limit to how far donor-recipient size mismatches can be taken before the risk of PGD overcomes the potential benefits of performing transplantation.
The only previously validated predictive model for the development of PGD is the RADIAL score (recipient: right atrial pressure > 10 mmHg, age > 60 years, diabetes and inotropic support dependence preoperatively; donor: age > 30 years; procedural: length of ischemia > 240 min) [6] . This system, however, is limited by poor calibration [9, 17] and the fact that it was derived and validated in a patient cohort with a low prevalence of VADs (16/655; 2%) as compared to a modern transplant practice. Patients with VADs prior to transplantation have been shown to be at increased risk for developing PGD [3, 5, 18] . Given the increased utilization of bridge-to-transplant therapy in the current era of heart transplantation, pretransplant mechanical circulatory support is a key factor to study when investigating PGD. One strength of our study, therefore, is that the prevalence of VADs in the study cohort (28%) better reflects the frequency of bridge-to-transplantation therapy that occurs in the contemporary treatment of heart failure [2] . We cannot comment on the calibration of our risk model, however, without first applying it to another population.
Unfortunately, due to the significant variability in definitions of PGD, eras of heart transplantation, and published study designs currently available, the best method to assess donor-recipient mismatch that portends increased risk for PGD remains to be determined [9] . The standardized criteria set forth by the ISHLT and validated in this study should be applied to large, contemporary series that include a high percentage of patients bridged with VADs in order to identify additional PGD risk factors and validate methods to assess the risk of PGD prior to transplantation.
The limitations of this report include those expected of a single-centre, retrospective study. Although the results in our patient cohort may not be readily generalizable to other populations, we are the first to apply the standardized criteria proposed by the ISHLT to define PGD. By implementing this definition, results of future studies can more easily be compared to the findings in this report. Furthermore, our patient population better represents the demographics of modern heart transplant patients: an increased prevalence of VADs was present in the study cohort as compared to previous investigations regarding PGD, though many centres have even higher proportions of transplant recipients bridged with VAD support [2] . Survival beyond 1-year follow-up was not available at the time of the current analysis, but the impact of PGD on mid-to-long term survival appeared to disappear by 3 months post-transplantation. However, a study with an increased duration of follow-up is necessary to confirm this finding.
The ISHLT consensus committee introduced into their criteria a distinction between PGD-RV and PGD-LV, a novel conceptualization of PGD that had not been previously utilized in the literature. We did not incorporate this distinction into our assessment of PGD in the study cohort. Our centre's clinical approach to patients with evidence of PGD precluded such analysis. The haemodynamic criteria required to distinguish PGD-RV from PGD-LV, specifically PCWP, is not routinely collected at our centre due to safety concerns. Furthermore, no RVADs were placed in our cohort because we prefer to initiate ECMO for all patients with PGD who require support beyond maximum inotropic therapy. Whether this is a limitation of our study or an additional limitation to the clinical relevance of the ISHLT criteria remains to be determined.
In conclusion, we identified a total PGD incidence of 30% in a series of adult cardiac transplantations performed at a highvolume centre using ISHLT diagnostic criteria. Patients with moderate/severe PGD (13%) had decreased survival, though complete graft recovery appeared to be achieved by 3 months following transplantation. Risk factors for the development of moderate/severe PGD included elevated preoperative creatinine, recipient hospitalized at time of transplantation and undersized donor hearts. Ultimately, the new ISHLT diagnostic criteria for PGD appear to identify and discriminate patients in a clinically relevant manner.
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